



STATUS

ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) - RDP PROGRAM

For up to date criteria and forms, please check: www.gov.bc.ca/pharmacarespecialauthority

Fax requests to 1 800 609-4884 (toll free) OR mail requests to: PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4

This facsimile is Doctor-Patient privileged and contains confidential information intended only for PharmaCare. Any other distribution, copying or disclosure is strictly prohibited. If you have received this fax in error, please write "MIS-DIRECTED" across the front of the form and fax toll-free to 1 800 609-4884, then destroy the pages received in error.

If PharmaCare approves this Special Authority request, approval is granted solely for the purpose of covering prescription costs. PharmaCare approval does not indicate that the requested medication is, or is not, suitable for any specific patient or condition.

Name and Mailing	RESCRIBER INFORMATIO		SECTION 2 - PATIEN	T INFORMA	TION	
Name and Mailing	Address	☐ Mail Confirmation	Patient (Family) Name			
			Patient (Given) Name(s)			
CPSBC OR (CRNBC License# (not MSP#) Phone	Number (include area code)	Date of Birth (YYYY / MM / I	DD)	Pate of Application	(YYYY / MM / DD)
CRITICAL FOR A			CRITICAL FOR PROCESSING		ealth Number (PHN)	
	ARBs (Complete Sections 1		NCE ARBs (Complete S			
such as candesarta	nge provided for PharmaCare eligib In 4 mg) are not PharmaCare benef REFERENCE ARBs (FULL CO	ts.	na combination products ar	e eligible for co	verage; nowever so	ome formulations
	experienced intractable cough or angioe		nzyme Inhibitor (ACF-I) Full cove	rage will be provi	ded for all First Line A	RBs
MEDICATION REQUESTE	ED (SELECT ONE)		<u> </u>			1105.
CANDE	SARTAN LC	SARTAN	TELMISARTAN	VA	LSARTAN	
SECTION 4 - I	NON-REFERENCE ARBs (PAI	RTIAL OR FULL COVERAG	iE)			
non-referer	experienced intractable cough or angionce ARBs (up to the daily drug cost for re				r, PARTIAL coverage v	vill be provided for
EPROS		MESARTAN 🔲 I	IRBESARTAN			
					La Laccon	
	ation of FULL coverage of non-re	_	Bs must have been unsucce	esfully tried as	pelow:	
REFERENCE ARB	candesartan	erence ARBs <u>ALL</u> reference ARE LOSARTAN	3s must have been unsucce	•		LSARTAN
4B. For considera REFERENCE ARB Discontinued due to:		_	TELMISA	•		LSARTAN Intolerance
REFERENCE ARB Discontinued	CANDESARTAN	LOSARTAN	TELMISA	RTAN	VA	
Discontinued due to: Approximate Dates of Trials:	CANDESARTAN	LOSARTAN Failure Intolera	TELMISA	RTAN	VA	
Discontinued due to: Approximate Dates of Trials:	CANDESARTAN Failure Intolerance	LOSARTAN Failure Intolera	TELMISA	RTAN	VA	
Discontinued due to: Approximate Dates of Trials:	CANDESARTAN Failure Intolerance	LOSARTAN Failure Intolera	TELMISA	RTAN	VA	
Discontinued due to: Approximate Dates of Trials:	CANDESARTAN Failure Intolerance ADDITIONAL COMMENTS	LOSARTAN Failure Intolera FOR CONSIDERATION C	TELMISA ince Failure DF COVERAGE	RTAN Intolerance	Failure	
Discontinued due to: Approximate Dates of Trials: SECTION 5 - A	CANDESARTAN Failure Intolerance	LOSARTAN Failure Intolera FOR CONSIDERATION Construction of the	TELMISA Ince Failure DF COVERAGE	RTAN Intolerance his Special Auth	Failure Failure	Intolerance
REFERENCE ARB Discontinued due to: Approximate Dates of Trials: SECTION 5 - A Personal information and in accordance wi Information and Prote the patient's consent. provide PharmaCare evaluate this and oth generally. If you have	CANDESARTAN Failure Intolerance ADDITIONAL COMMENTS PRESCRIBER SIGNATURE on this form is collected, used and disclose the the British Columbia Pharmaceutical Serction of Privacy Act. It will not be disclosed in the information you provide will be relevable to the medication requested, (b) er Ministry programs, and (c) to manage a er any questions about the collection or use	LOSARTAN Failure Intolera PharmaCare may request additional addunder the authority of, vices Act and Freedom of to any persons without int to and used solely to (a) to implement, monitor and ind plan for the health system of this information,	TELMISA ince Failure DF COVERAGE	his Special Auth patient that tre is to obtain	Failure Failure ority request. he purpose of reil Special Authori	Intolerance
Personal information and in accordance will Information and Prote the patient's consent. provide PharmaCare evaluate this and oth generally. If you have call Health Insurance	CANDESARTAN Failure Intolerance ADDITIONAL COMMENTS PRESCRIBER SIGNATURE on this form is collected, used and disclos th, the British Columbia Pharmaceutical Ser ction of Privacy Act. It will not be disclosed The information you provide will be releva- benefits for the medication requested, (b) er Ministry programs, and (c) to manage a	LOSARTAN Failure Intolera PharmaCare may request additional addunder the authority of, vices Act and Freedom of to any persons without int to and used solely to (a) to implement, monitor and id plan for the health system of this information, om elsewhere in BC toll free at	TELMISA Ince Failure DF COVERAGE al documentation to support to the information to PharmaCa	his Special Auth patient that tre is to obtain coses set out	Failure Failure ority request. he purpose of reil Special Authori	Intolerance

EFFECTIVE DATE (YYYY / MM / DD)

DURATION OF APPROVAL